Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 311-321

  Qu, Ying ^a,b   Wang, Jinhua ^a   Sim, Myung Shin ^a   Liu, Bingya ^b   Giuliano, Armando ^a   Barsoum, James ^c   Cui, Xiaojiang ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Synta Pharmaceuticals Corp   (United States)

Author keywords

Akt; Apoptosis; Chemotherapy; Elesclomol; JNK; Reactive oxygen species

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; ELESCLOMOL; ESTROGEN; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; LIVIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIUM CELL; FEEDBACK SYSTEM; GROWTH INHIBITION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DOXORUBICIN; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; HYDRAZINES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 77953025849     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0470-6     Document Type: Article

References (49)

1. Lawson DH, Gonzalez R, Weber RW, Hutchins LF, Anderson CM, Williams KN et al. (2008) 2-Year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM). 2008 ASCO Annual Meeting. J Clin Oncol 26 (May 20 suppl): abstr 20023
2. Agarwala SS, Haddad J, Jacobson E (2008) Integrated safety analysis of elesclomol (formerly STA-4783) co-administered with paclitaxel. 2008 ASCO Annual Meeting. J Clin Oncol 26 (May 20 suppl): abstr14595
3. Tuma RS (2008) Reactive oxygen species may have anti-tumor activity in metastatic melanoma. J Natl Cancer Inst 100:11-12
4. Holmgren A, Johansson C, Berndt C, Lonn ME, Hudemann C, Lillig CH (2005) Thiol redox control via thioredoxin and glutaredoxin systems. Biochem Soc Trans 33:1375-1377 (Pubitemid 41779691)
5. Ambrosone CB (2000) Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2:903-917
6. Mittler R (2002) Oxidative stress, antioxidants and stress tolerance. Trends Plant Sci 7:405-410
7. Schumacker PT (2006) Reactive oxygen, species in cancer cells: live by the sword, die by the sword. Cancer Cell 10:175-176 (Pubitemid 44311072)
8. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al. (2009) Association of reactive oxygen species levels and radioresistant in cancer stem cells. Nature 458:780-783
9. Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, Zhang M et al (2008) Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 7:2319-2327
10. Biaglow JE, Miller RA (2005) The thioredoxin reductase/thioredoxin system.: novel, redox targets for cancer therapy. Cancer Biol Ther 4:6-13
11. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM et al (2003) A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4:463-476 (Pubitemid 38050043)
12. Foley K, Allen I, Bertin J, Kwan C, Inoue T, Kirshner J et al. (2007) The Oxidative stress inducer elesclomol (formerly STA-4783) enhances the In vivo efficacy of multiple anti-cancer therapies in mouse tumor models. AACR-NCI-ECORT International Conference on Molecular Targets and Cancer Therapeutics, abstr 159
13. Fang J, Nakamura H, Iyer AK (2007) Tumor-targeted induction of oxystress for cancer therapy. J Drug Target 1.5:475-486 (Pubitemid 47213870)
14. Hauschild A, Eggermont AM, Jacobson E, O'Day SJ (2009) Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). 2009 ASCO annual meeting. J Clin Oncol 27(suppl):abstr LBA9012
15. Greco WR, Park HS, Rustum YM (1990) Application of a new approach for the quantitation of drug synergism to the combination of cis- diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 50:5318-5327
16. D'Autreaux B, Toledano MB (2007) ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8:813-824 (Pubitemid 47462134)
17. Fornari FA Jr, Jarvis DW, Grant S, Orr MS, Randolph JK, White FK et al (1996) Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol 51:931-940 (Pubitemid 26109490)
18. Soldani C, Scovassi AI (2002) Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7:321-328 (Pubitemid 34832256)
19. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331
20. Mao X, Yu CR, Li WH, Li WX (2008) Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Ablpositive chronic myelogenous leukemia (CML) cells. Cell Res 18:879-888
21. Yi J, Yang J, He R, Gao F, Sang H, Tang X et al (2004) Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 64:108-116 (Pubitemid 38114088)
22. Potapova O, Gorospe M, Dougherty RH, Dean NM, Gaarde WA, Holbrook NJ (2000) Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol 20:1713-1722 (Pubitemid 30100190)
23. ChenN,NomuraM,SheQB,MaWY,BodeAM,WangLetal(2001) Suppressionofskintumorigenesisinc-JunNH(2)-terminalkinase-2-deficientmice. CancerRes61:3908-3912(Pubitemid32720949)
24. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ et al (2007) Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 211:439-446 (Pubitemid 46332555)
25. Sauer H, Wartenberg M, Hescheler J (2001) Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 11:173-186 (Pubitemid 32786086)
26. Gehrmann M (2006) Drug evaluation: STA-4783 - enhancing taxane efficacy by induction of Hsp70. Curr Opin Investig Drugs 7:574-580
27. Liu M, Aneja R, Liu C, Sun L, Gao J, Wang H et al (2006) Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells. J Biol Chem 281:18090-18097 (Pubitemid 44035609)
28. Ramos J, Sirisawad M, Miller R, Naumovski L (2006) Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation. Mol Cancer Ther 5:1176-1182 (Pubitemid 43881309)
29. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB et al (2003) Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17:575-588
30. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M (2004) Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/ Akt pathway. Ann Oncol 15:1510-1516 (Pubitemid 39409742)
31. Berkenblit A, Eder JP Jr, Ryan DP, Seiden MV, Tatsuta N, Sherman ML et al (2007) Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 13:584-590 (Pubitemid 46225365)
32. Honore S, Pasquier E, Braguer D (2005) Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 62:3039-3056 (Pubitemid 43004753)
33. Alexandre J, Batteux F, Nicco C, Chereau C, Laurent A, Guillevin L et al (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119:41-48
34. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67:3512-3517 (Pubitemid 46762129)
35. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B (2000) Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol. Chem 275:33585-33592
36. YangL,CaoZ,YanH,WoodWC(2003) Coexistenceofhighlevelsofapoptoticsignalingandinhibitorofapoptosisproteinsinhum antumorcells:implicationforcancerspecifictherapy.CancerRes63: 6815-6824(Pubitemid37322964)
37. NomuraT,MimataH,TakeuchiY,YamamotoH,MiyamotoE,NomuraY(2003) TheX-linkedinhibitorofapoptosisproteininhibitstaxol- inducedapoptosisinLNCaPcells.UrolRes31:37-44(Pubitemid36604901)
38. Gabellini C, Pucci B, Valdivieso P, D'Andrilli G, Tafani M, De Luca A et al (2006) p27kip1 overexpression promotes paclitaxelinduced apoptosis in pRb-defective SaOs-2 cells. J Cell Biochem 98:1645-1652 (Pubitemid 44141866)
39. Koh J, Kubota T, Koyama T, Migita T, Hashimoto M, Hosoda Y et al (2003) Combined anti-tumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo. Breast Cancer 10:260-267
40. Finkel T (2000) Redox-dependent signal transduction. FEBS Lett 476:52-54
41. Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, Fiscella M et al (1995) A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 270:29386-29391
42. Jolly C, Morimoto RI (2000) Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 92:1564-1572
43. Park HS, Lee JS, Huh SH, Seo JS, Choi EJ (2001) Hsp72 functions as a natural inhibitory protein of c-Jun N-terminal kinase. Embo J 20:446-456 (Pubitemid 32126980)
44. Ravagnan L, Gurbuxani S, Sushi SA, Maisse C, Daugas E, Zamzami N et al (2001) Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 3:839-843
45. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67:1979-1987
46. Liang K, Lu Y, Li X, Zeng X, Glazer RI, Mills GB et al (2006) Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol 70:1045-1052
47. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L et al (2003) HER2/PI-3 K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22:3205-3212
48. Li X, Lu Y, Liang K, Liu B, Fan Z (2005) Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res 7:R589-R597
49. Tari AM, Mehta A, Lopez-Berestein G (2001) Modulation of Akt activity by doxorubicin in breast cancer cells. J Chemother 13: 334-336